Iqvia Stock Forecast, Price & News

Iqvia's stock was trading at $125.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IQV stock has increased by 25.3% and is now trading at $157.12.
View which stocks have been most impacted by COVID-19.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 1 hold rating and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Iqvia.

Iqvia is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Iqvia.

Iqvia Holdings Inc (NYSE:IQV) announced its quarterly earnings results on Wednesday, July, 22nd. The medical research company reported $1.18 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.06 by $0.12. The medical research company earned $2.52 billion during the quarter, compared to analyst estimates of $2.41 billion. Iqvia had a net margin of 1.21% and a return on equity of 17.90%. During the same period in the previous year, the firm earned $1.53 EPS.
View Iqvia's earnings history.

Iqvia issued an update on its FY20 earnings guidance on Wednesday, July, 22nd. The company provided earnings per share guidance of $6.10-6.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.87. The company issued revenue guidance of $11.0-11.1 billion, compared to the consensus revenue estimate of $10.73 billion.

17 equities research analysts have issued 1 year price targets for Iqvia's shares. Their forecasts range from $110.00 to $200.00. On average, they anticipate Iqvia's share price to reach $165.00 in the next year. This suggests a possible upside of 5.0% from the stock's current price.
View analysts' price targets for Iqvia.

Some companies that are related to Iqvia include Incyte (INCY), PPD (PPD), EXACT Sciences (EXAS), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Medpace (MEDP), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL) and Luna Innovations (LUNA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), NVIDIA (NVDA), Endologix (ELGX), Micron Technology (MU), Chipotle Mexican Grill (CMG), Alibaba Group (BABA), Paypal (PYPL), salesforce.com (CRM) and Accenture (ACN).

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.75%), BlackRock Inc. (7.22%), Jackson Square Partners LLC (2.05%), Canada Pension Plan Investment Board (1.24%), Nuveen Asset Management LLC (1.15%) and FMR LLC (1.09%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, John Connaughton, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer, Ronald E Bruehlman and W Richard Staub.
View institutional ownership trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, Man Group plc, Canada Pension Plan Investment Board, Goldman Sachs Group Inc., FMR LLC, Nuveen Asset Management LLC, Marshall Wace LLP, and Macquarie Group Ltd.. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Michael J Evanisko, and Michael R Mcdonnell.
View insider buying and selling activity for Iqvia.

IQV stock was purchased by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, Vanguard Group Inc., State of Tennessee Treasury Department, Nordea Investment Management AB, Bessemer Group Inc., Alyeska Investment Group L.P., Veracity Capital LLC, and Ninety One North America Inc..
View insider buying and selling activity for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $157.12.

Iqvia has a market capitalization of $30.05 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe.

The official website for Iqvia is www.iqvia.com.

Iqvia's mailing address is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]